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ABSTRACT 
 
Local farming communities throughout the world face productivity constraints, 
environmental concerns, and diverse nutritional needs. Developing countries address these 
challenges in a number of ways. One way is public research that produces genetically modified 
(GM) crops and recognize biotechnology as a part of the solution.  To reach these communities, 
GM crops, after receiving biosafety agreement, must be approved for evaluation under local 
conditions. 
However, gaps between approvals in the developed and developing world grow larger, as 
the process of advancing GM crops in developing countries becomes increasingly difficult. In 
several countries, only insect resistant cotton has successfully moved from small, confined 
experimental trials to larger, open trials and to farms. By far, most GM crop approvals have been 
for commercial products that perform well under tropical conditions. 
However, complete information on public GM crop research in developing countries has 
not been assessed. ￿Will policies and research institutions in the developing world stimulate the 
safe use of publicly funded GM food crops?￿ The relatively few GM crops approved from public 
research, coupled with growing regulatory, biosafety capacity, trade, and political concerns, 
argue to the contrary. 
To tackle this issue, we identified and analyzed public research pipelines for GM crops 
among 16 developing countries and transition economies. Respondents reported 209 genetic 
transformation events
1 for 46 different crops at the time when the survey was conducted. The 
pipelines demonstrate scientific progress among publicly funded crop research institutes in 
participating countries. Information and findings are presented for GM crops nearing final stages 
of selection. Additional details are provided for the types of genes and traits used, the breadth of 
genetic resources documented, implications for regulation, and the type of research partnerships 
employed. 
Regulations, GM crop approvals, choice of transgene, and policy implications are 
discussed as they affect this research. Based on these findings, recommendations are presented 
that would help sustain and increase efficiency of publicly supported research while meeting 
biosafety requirements. To do so, the study examines results concerning investments and choices 
made in research, capacity, and policy development for biotechnology. These indicate the risk 
and potential for GM technologies in developing countries. Policy makers, those funding 
biotechnology, and other stakeholders can use this information to prioritize investments, consider 
product advancement, and assess relative magnitude of potential risks, and benefits. 
 
Keywords: biosafety; regulation; biotechnology; genetic modification; public research
                                                 
1 The definition of an event, as used in this study, means the stable transformation (incorporation of foreign DNA 
into a living plant cell) undertaken by a single institute among the participating countries, thereby providing a 
unique crop and trait combination. 
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1.  INTRODUCTION 
Working with limited human resources and financial restrictions (Falck-Zepeda et al. 
2002), scientists across the developing world are making important gains in biotechnology 
research. Over the past 10 to 15 years, scientists in developing countries have been applying new 
genetic technologies to a diverse range of crops and traits. Many of these new technologies hold 
promise for addressing productivity constraints faced by smallholder, resource-poor farmers. 
This is accomplished by transforming local or foreign (imported) plant varieties to provide new 
opportunities for socioeconomically diverse farming systems. Publicly funded institutes in 
developing countries, that rely to various degrees on national, international and private partners, 
lead this research. 
Most studies regarding the impact of genetically modified (GM) crops
3 have focused on 
commercial biotechnology or seed company products used primarily in four industrialized 
nations ((Falck-Zepeda et al. 1999; 2000). This study focuses on GM crop pipelines derived from 
publicly funded research in developing countries. It provides essential information regarding GM 
crops under development, status of biosafety approvals, implications of genes to be deployed, 
distribution of seed or improved planting material, and the range of partnerships available. 
                                                 
2 Corresponding Authors , Joel Cohen, j.cohen@cgiar.org  and Patricia Zambrano  p.zambrano@cgiar.org. 
3  Genetic modification allows selected individual genes to be transferred from one organism into another, including 
genes from unrelated species. The technology can be used to promote a desirable crop character or to suppress and 




However, detailed information on the institutes developing these GM crops is lacking, making 
technology assessments and progress difficult to assess.  
Currently, the number of GM crops that have been approved and are cultivated in the 
developing world is largely limited to insect-protected cotton in Argentina, China, India, Mexico, 
and South Africa. Virtually all of this improved seed is available from commercial providers, 
with the exception of China, where publicly developed seed is available as well (Huang et al. 
2002). Growers in these countries include poor, smallholder farmers (Thirtle et al. 2003). One 
reason why the approval and use of insect-protected cotton is widespread is that cotton is not a 
food crop, but rather used for fiber, oil and livestock meal. Consequently, most regulatory 
authorities in developing countries have found it easier to approve this crop because they are not 
required to assess food safety￿an area in which few developing country regulatory authorities 
feel competent.  The exceptions to this are South Africa and the Philippines where assessments 
have been conducted. 
 Approvals of transgenic crops for use as food or feed, lag behind those for non-food 
crops.  Among developing countries and transition economies, only three have approved a single 
transgenic event  (soybean in Brazil, Czech Republic and Uruguay; maize in the Philippines), 
while two have approved two events (soybean and tomato in Mexico; soybean and maize in 
South Africa) and one, Korea, has approved three events (one in soybean and two in maize). Pre-
commercial cultivation of GM soybeans in Romania and GM maize in Bulgaria and Honduras 
also took place last year.  Argentina, the world’s second largest producer of transgenic crops by 
acreage, stands alone amongst the developing countries in having approved planting for seven 




different transgenic events have received approvals for planting in developing economies (Annex 
1), compared with 79 events in 14 different food/feed crops in developed countries (Annex 2). 
Yet, much has been accomplished over the past decades of investment in agricultural 
biotechnology research. In order to assess this status of publicly-developed GM crops
4 in 
developing countries, the International Service for National Agricultural Research (ISNAR) 
initiated a study entitled Next Harvest.  This research shows that 76 public institutions in 16 
participating countries have stably transformed 46 crops, incorporating a wide range of genes for 
insect, fungal, viral, and bacterial resistance; protein and quality improvements; herbicide 
tolerance, and salt and drought stress. Despite progress, however, the primary source of GM 
crops continues to be the private sector. Multinational companies lead in the development of GM 
technologies and, given the technology￿s market potential, have invested significant resources in 
facilitating technologies through regulatory processes. With the exception of China, public 
research products lag behind, causing concern when private investments are not finding their 
way to countries, crops, traits and technologies that are most relevant to small-scale, resource-
poor farmers. 
Unless products developed by public research in developing countries gain similar 
approval as those developed by the private sector, many GM crops will not reach farmers and the 
impact of public sector biotechnology research in developing countries will remain negligible. 
This could mean that transgenic research would remain absent among alternative technologies 
foreseen to meet the growing agricultural demands, as in the case of China (Tso 2004), and that 
all potential benefits from this research could bypass the poor. 
                                                 
4 In this context, publicly developed GM crops are those developed by public or national institutes, including 




The Next Harvest study addresses these points by examining in detail GM
 crops emerging 
from public research pipelines in 16 countries with developing or transitional economies. The 
focus of this study is placed on food crops, with the inclusion of cotton, since it is a valuable 
cash crop for some small-scale, resource-poor farmers in certain developing countries.  
Specific crops and traits are described, grouped by continent, phenotypic category, and in 
relation to crops researched by centers of the Consultative Group for International Agricultural 
Research (CGIAR). The type of genetic resources used for transformation is documented. Events 
are also grouped by their location in the stages of regulatory processes with those in confined 
field-testing are examined in more detail. 
 
2.  METHODOLOGY 
Biotechnology can be defined quite broadly
5 allowing room for future technologies that 
may prove at least as useful as genetic modification of crops.  In the future, as useful genes 
within the same or similar genomes become available, safety requirements for crops engineered 
with these genes may also change. Such crops would pose less public concern, since the genes 
used for transformation would be plant genes from known food crops and therefore have a 
history of safe use. 
However, due to regulatory, safety, access, dissemination, and funding considerations, it 
is critical to understand the status of GM crops being developed for use by and for developing 
countries. Next Harvest was initiated in the beginning of 2002 to determine expectations and 
                                                 
5 For example, Biotech Life Science Dictionary of the University of Texas Institute for Cellular and Molecular 
Biology, defines biotechnology  as : ￿The industrial use of living organisms or biological techniques developed 
through basic research. Biotechnology products include antibiotics, insulin, interferon, recombinant DNA, and 
techniques such as waste recycling. Much older forms of biotechnology include breadmaking, cheesemaking and 




limitations on public GM crops and traits in 16 selected developing countries.  Next Harvest
' 
focuses on crop research data through 2003.   
Recently, broader inventories have been compiled, especially that of FAO, which in 2003 
launched an online database on Biotechnology in Developing Countries (FAO-BioDeC)
6 to 
monitor trends in the development, adoption and application of crop biotechnologies in 
developing countries. Other studies include Johansen and Ives (2001) and Alhassan (2003) for 
Africa, an Asian Development Bank report for Asia (ADB 2001) and a report on Latin America 
(Trigo et al. 2002). International Service for the Acquisition of Agri-biotech Applications 
(ISAAA)
7 prepares annual overview reports on the extension of global adoption of GM 
technologies and area planted worldwide 
ISNAR reports (see for example, Falconi 1999; and, Komen et al. 2000 for summaries of 
findings) captured information on ongoing crop biotechnology projects and indicators of 
available capacity in a range of developing countries. Other reports include data and examples of 
GM crops for developed/developing countries, as cited in the Pew Initiative on Food and 
Biotechnology (Pew Initiative 2001), and the Nuffield Council on Bioethics (2004). 
This study sampled programs and institutes in a limited number of countries so that a 
careful examination of data was possible. While useful for some purposes, sampling from a full 
range of initiatives in each country would not generate information with the level of detail and 
accuracy desired by ISNAR and partners. Extensive variation in the type and state of technology 
developed can mean differences in how data are collected and reported.  
To ensure that relevant knowledge, experiences, and insight were captured in the study, 
an expert survey approach was used. Given the fact that the development of biotechnology 
                                                 
6 http://www.fao.org/biotech/inventory_admin/dep/default.asp 




products is knowledge and resource-intensive, the survey was directed to pre-selected experts 
with unique expertise and knowledge due to their position and involvement in their countries. 
Another goal was served by this method: the development of a longer-term research partnership 
and involvement of key stakeholders in monitoring and assessing their own work. 
Researchers and/or regulators in the 16 partner countries listed in Table 1 implemented 
the survey. In a joint effort with the International Food Policy Research Institute (IFPRI), the 
study team analyzed the information and consulted further with scientific and research leaders in 
their respective countries. Collection of information was coordinated with key national research 
organizations. A methodology was then developed for its analysis. 
Fourteen of these countries were represented at a Next Harvest meeting, held in The 
Hague, in October 2002. At this meeting, participants examined preliminary data, standardized 
data entry procedures, and defined methodologies and validation for final collection and analysis 
(Luijben and Cohen 2002). With IFPRI￿s participation, further iteration and consultations were 
undertaken to update and finally validate all data for each country. 
Experts collected data across five categories: 
1.  Information Collection.  Continent, country and lead institute provided details on GM 
crop development. Table 1 shows the total number of events included in the final 
assessment for each country. This information also allows for within country and regional 





























    
2.  Description of crops under research, transgenes deployed, and the desired phenotypic 
trait. Crops were categorized and sorted following the FAOSTAT crop classification.
8 
Transgene data were gathered as specifically as possible for each gene, but in a few cases 
such detail was either not clear or listed as ￿confidential￿. Information was also collected 
for phenotypic trait expression.
9 Where possible, detailed information at the gene level 
was obtained. If, for example, the trait being described was virus protection in papayas, 
the study team recorded the means by which the trait was conferred, (here a coat protein 
gene), and the specific virus against which the trait was developed (here, the papaya ring 
spot virus). 
3.  Types of genetic resources used for transformation were reported, enabling the team to 
determine whether these resources were developed by a public institution or private firm, 
and whether their original was local or foreign (imported). 
4.  The relation between regulatory processes and GM research. To accomplish this, data 
were collected by regulatory stage, emphasizing the most advanced events possible. Four 
                                                 
8http://apps.fao.org/faostat/form?version=ext&collection=Production.Crops.Primary&Domain=Production&languag
e=EN&servlet=1&axis=item&xsl=areareflist 
9 Phenotypic traits were categorized as per USDA APHIS classification. ￿Phenotype/Phenotype Category - the 
nature of the introduced trait. Each is assigned a two-letter code which describes the category into which the trait 
falls, as determined by the Animal and Plant Health Inspection Service (APHIS)￿ See 




stages were used: experimental, confined field trial, scale-up, or commercial release. For 
experimental stage entries, experts were asked to identify only highly developed 
biotechnologies coming from laboratory, greenhouse, or glasshouse. 
5.  The type of collaboration developed (if any), and plans for dissemination of research 
outputs.  Questions asked included the number of institutions involved, the type of 
collaboration developed and the plans for dissemination. The study team developed data 
collection and validation methodologies for information about specific countries, crops, 
and gene/technology combinations. This led to classification of data as unique 
transformation events. These single, unique transformation events represent a 
combination of crop, transgene, lead research institute, and the specific country of origin. 
This definition recognizes both the transformation event and its institutional context.  Not 
all possible events are summarized here, as the study is designed to be illustrative of 
trends, not an attempt to capture each and every transformation event under testing or 
production in the participating countries.  
 
As we have set a very high standard for the laboratory/greenhouse stages we cannot 
account for all the technologies in the research pipeline, particularly before proof of concept has 
been presented. As such, the survey cannot measure the flow of technologies from one stage to 
the next, nor can it tell whether technologies are getting stuck in a particular stage. 
 
3.  PIPELINES FOR GM CROPS AND TRANSGENES EMPLOYED  
To date, our research includes 209
10 transformation events from 76 scientific institutes in 
16 countries. Such institutions in China, South Africa, Indonesia, India, and Argentina accounted 
for over half of the events recorded (Figure 1). These countries maintain an ongoing commitment 
to biotechnology research, supported by universities and agricultural research institutes with 
good laboratory and agronomic capacity.
11  
                                                 
10 Total number of events initially reported was 255.  However, this number was reduced since some reported 
events were too premature in their development, or information could not be clarified, or because data was missing. 
Thus, the total number reported here are 209. 
11 The sources of investment and funding for this work are the subject of a parallel study (Falck et al. 2002), which 






















Transformation events organized by crop groups are shown in Figure 2. While 
transformation of cereals predominates, there are significant numbers of transformation events 
for fruits, roots and tubers, and vegetables, with each group representing a diverse set of crop 
species. Further, progress in transformation of indigenous crops, many captured in the ￿all 
others￿ category, including alfalfa, mung beans, beans, chickpeas, cowpeas, lupin, cacao and 
coffee, are also significant in number.  The greatest numbers of transformation events to date are 
for rice (17.7 percent) potatoes (11.0 percent), maize (8.6 percent), and papayas (6.2 percent).




























Transformation of crops organized by CGIAR Centers￿ mandates is shown in Figure 3. 
While public research efforts are responsible for transformation of 46 crops worldwide, only 15 
of these crops are the subject of CGIAR Center and NARS research. Over half of all public 
transformation events (55 percent) are concentrated among these 15 crops.  The remaining 45 
percent of transformation events involve 31crops outside the CGIAR Centers￿ mandate, 
including cotton, vegetables, and fruits.  
Figure 3--Comparison of events among participating countries with crop transformation at 



































 The percentage distribution of events by phenotypic groups is presented in Figure 4. 
Over half of the 209 events included in the data set involved single genes that confer either viral 
or insect resistance to the host plant. In only a small number of cases (11 events) were multiple 
(stacked) genes being developed for phenotypic combinations, such as those that simultaneously 
confer insect resistance and herbicide tolerance. 





















AP- Agronomic Properties; BR- Bacterial Resistance; FR- Fungal Resistance; HT- Herbicide Tolerance; IR- Insect 




3.  GENETIC RESOURCES 
 Novel genes are just one piece of the biotechnology puzzle. Equally important is access 
to genetic resources that possess acceptable agronomic performance characteristics and are 
suitable for transformation. In commercially-oriented biotechnology, genes are typically 
introduced into elite, or proprietary lines containing traits of local or national value, derived from 
years of conventional plant breeding. However, for public scientists in developing countries, 






















such material without licensing and remuneration. Such conditions, coupled with inadequate 
technology transfer agreements available for public research, may mean that the costs to farmers 
for such seed would be beyond their ability to pay.  
To better understand the source and use of genetic resources, the survey asked experts if 
material used in the transformations was of local or foreign origin, and, whether it was from 
public or private sources.
12 Study results show that 85 percent of the genetic resources used for 
transformation were of local public derivation (Figure 5). Public genetic resources, usually 
thought of as locally adapted and well preferred by farmers, were identified for all 47 crops, 
including cotton. These genetic resources are usually free from any varietal or intellectual 
property claims. Their transformation is an indication of remarkable achievement, as our data is 
obtained only from well-advanced material, indicating the ability not only to transform, but also 
to express stable genes and traits, over several generations. 
                                                 
12 Local genetic resources constitute landraces, varieties and finished lines produced or derived from developing 
countries; foreign (or imported) resources are those brought to a developing country by an external entity. Public 
materials are those from any form of public institution, and private are those from companies, as well as commodity 

















Does the high percentage of local transformed material mean reliance or dependence on 
public genetic resources or, a deliberate independence from protected varieties or commercial 
germplasm? This question is not easy to answer, as both choices present benefits and costs, and 
different opportunities to the research institute. On the one hand, the ability to transform local, 
widely used public or indigenous genetic resources, among the 46 crops, provides the potential 
for greater public and farmer acceptance. Using well performing GM public germplasm means 
that farmers will not be prevented from saving seeds, nor will they be under the potential of 
monopoly pricing of seeds. The choice of using public or private genetic resources also depends 
on whether transformed lines are as productive and competitive as other available material 
(public or private), or if they were selected due to ease of regeneration.  
Access to private or commercial genetic material is extremely limited, as only 9 percent 
of all transformation events used such material. The limited exchange of genetic materials 




research projects between the public and private sector (See Section 9). For many crops, there 
are few productive alternatives to the genetic resources currently in use, as very little selection 
and adaptation is being done through either public or private research.  
Once genes are stable in a particular background, backcrossing them with productive and 
accepted local genetic resources will ensure that transgenes are suitable for local situations. 
Companies will look for the best available lines of the backcrossing process, seeking plants that 
are adapted and productive for farmers. In Brazil, for example, extensive backcrossing by several 
companies and Embrapa is transferring genes for development (see Section 9). 
Examination of benefits and cost may be needed to determine if the potential 
contributions of local genetic resources or locally adapted genes may need intellectual property 
protection. Benefit distribution and the extensive use and success in transforming local genetic 
resources, can form the basis for research agreements between public institutes and commercial 
GM producers. Creating clear benefit streams would also facilitate south-south transfer by 
minimizing the fear of economic loss, or germplasm used without sufficient agreement.   
 
5.  ENSURING SAFETY IN THE FIELD 
To examine the relationship between the transgenic events reported above and biosafety 
regulations for GM crops, the survey proposed a well-defined set of regulatory stages to classify 
each product, especially regarding field-testing and advancement. Respondents were asked to 
indicate in what stage of regulation their respective events were most accurately placed.  
Events in the experimental stage contain stable research products derived from multiple 
generations, beginning in the laboratory and moving to the greenhouse or glasshouse. In this 




expression of traits remains stable in small-scale, single or multi-location confined trials. These 
trials are designed to mitigate any environmental damage by their containment, thus their 
regulatory standards are different from those established for subsequent stages. 
 The scale-up stage occurs when products advance from confined trials to pre-
commercial trials, requiring the ability to increase seed amounts, and larger areas for testing 
purposes. These tests may be conducted for environmental safety purposes, efficacy trials, or 
both. Finally, products are made available to farmers only after commercial release, through 
privately- or publicly-owned seed companies or other institutional mechanisms.  
Survey data show that a total of 127 events are at the experimental stage, while 44 are in 
confined trials, 22 in scale-up testing (mostly in China), and seven in the commercial release 
stage (Figure 6).
13  
In all research pipelines, technologies or products are eliminated due to safety 
considerations or efficacy questions. For example, in pharmaceutical safety processes, 1 in 5 
investigational drugs make it from human studies Phase I to commercialization (DiMasi, et al. 
1999). However, in the case of GM crops, many countries have only interim guidelines or 
regulations in place, most of which do not allow for commercial approvals. Other countries, with 
commercial approval abilities, often lack confidence in their commercial decision-making. Such 
decisions are influenced by negative public opinion, pressure from anti-GM groups, and the 
current trade impasse over GM crops between the USA and Europe (CompØs L￿pez and Carrau 
2002). There may also be physical limitations such as growers inability to produce adequate seed 
amounts for large scale testing or for food safety testing.  
                                                 
13 Nine transformation events could not be grouped among these stages, as these particular events were sidelined 
due to outstanding issues, some being agreement on intellectual property rights, or await further data before entry 





Those events in the confined testing represent the most promising public research for GM 
crops (Figures 2 and 4). These 44 events will decline in number during their rigorous evaluation 
and of those listed only seven countries have five or more trials in place. However, the public 
sector cannot just monitor confined trials for safety and efficacy. It must also guarantee seed 
supplies to evaluate product performance on a large scale, and include experiments designed 
specifically for safety evaluation.  However, many of the events recorded have been in multiple 
years of testing and are waiting approvals for scale-up or pre-commercial trials. These larger 
tests could be done in partnership with private seed companies or with government seed 
production facilities. To accomplish this successfully, events should be identified as soon as 
possible, based on the most reliable field trial data possible.  
We do not know the number of initial transformation events required to reach the event 
records in Figure 6. In fact, industry experience points to a ratio of transgenic events to useful 
released products of 100:1 (Quemada, personal communication 2004). Are the 44 events in 
confined testing, spread over many crops, traits and countries, sufficient to select superior GM 
material, increase seed, biosafety trials, and finally, advancement to commercial use? 
Implications of these numbers and ratios require analysis among participating countries and 
institutes, as it would allow institutes to assess their role from a development perspective and not 













6. SAFETY, REGULATION, AND REQUIRED ASSESSMENTS  
The most important benefit of biosafety regulation is ensuring that biotechnologies 
deployed in a country are safe and effective. In addition, a well functioning regulatory system 
can instill confidence in the public that the risk assessment used to evaluate newer technologies, 
including biotechnologies, are science-based, as presented under Article 15 and Annex III of the 
Cartagena Protocol on Biosafety (Convention on Biological Diversity (CBD)Secretariat 2000). 
While the Protocol provides a unifying approach to biosafety, it also states that the cost of the 
assessment is borne by the notifier (Article 15).  
For this reason, the study explores the benefits and costs of regulation, especially those 
relevant to public institutions providing GM crops in the developing world. These institutions 
have little combined experience as ￿notifiers￿ and are only just beginning to understand the 
safety costs associated with those required for research and development. As all participating 
institutes place safety paramount, they wish to understand costs to the notifier as well as to 
















social value are not approved, and hence not able to provide its net benefits to society. To initiate 
the exploration of safety and the costs of biosafety regulations, certain participants were able to 
give basic estimates of costs they face as they seek to fulfill safety requirements while 
developing their specific technologies and crops. In reviewing this data, some preliminary 
findings became apparent. 
A study of Brazil by Sampaio (2002) estimates the compliance costs for regulatory 
approval of single events. These cost estimates include the initial green house and field 
screening, field testing for environmental impact, and food safety measured in US dollars. The 
average annual cost of compliance per event varied from US$ 140,000 for virus-resistant papaya, 
to US$ 800,000 for herbicide- resistant soybeans. The higher cost for herbicide resistant 
soybeans is mainly due to the requirement of performing complete animal studies.  A study of 
Costa Rica by Sittenfeld (2002) estimated the average annual cost for virus-resistant rice at US$ 
680,000. This estimate does not include costs associated with development of the technology. 
Data presented from Brazil contains information for food safety testing needed for 
regulatory approval. While there were not many other examples of such tests, the need for food 
safety information, the policy and regulatory decisions affecting these requirements, and the 
severe lack of capacity for such in developing countries was also discussed (Cohen et al. 2003). 
For this reason, among others, the Cartagena Biosafety Protocol envisions the need for capacity 
building among regulatory bodies as a central activity (CBD 2001). 
A study by Odhiambo (2002) estimated the cost for an insect resistant corn event in 
Kenya at US$ 160,000. The major component of which is the cost of containment structures. 
Sutrisno et al. (2002) presented data for insect resistant corn and cotton, herbicide resistant corn 




Indonesia ranges from US$ 390,000 to US$ 420,000. Quemada (2003) estimated that the total 
cost for the biosafety regulatory compliance of virus resistant potatoes in South Africa amounted 
to US$ 830,000.  
These estimates rely on the state of knowledge and the current biosafety regulatory 
system in the respective countries as presented during the first Next Harvest conference in 2002. 
As knowledge, experiences, and exchange of information continue to grow, increased familiarity 
with GM technologies will enable regulatory agencies to have confidence to reduce 
requirements, thereby decreasing the approval costs per event.  Participants noted that there has 
been a shift of regulatory costs to earlier stages of the research process. This fact highlights the 
need to rationalize GM research efforts by being more selective as to projects and numbers of 
events so that safety requirements can be completed. Participants also noted the importance of 
ensuring that the cost structure and level of regulatory processes are adequate to assure safety, 






Table 2--Preliminary estimates of average per year per event costs of biosafety regulations 
among five countries 
 
Country Average  per  year 





1  0.14-0.8  Virus resistant papaya and 




2  0.68  Virus resistant rice  Sittenfeld (2002) 
Indonesia  0.039-0.042  Insect resistant corn and cotton, 
herbicide resistant corn and 
soybeans 
Sutrisno, Herman, 
Moeljopawiro, Loedin (2002) 




0.83  Virus resistant potatoes  Quemada (2003) 
Notes: 
1 Brazil does not include infrastructure investments. Variation in costs is related to safety assessment of events tested for food 
safety outside the country (e.g. glyphosate resistant soybean), or events for which research and development to the market are 
done in Brazilian laboratories.  
2 Costa Rica includes molecular characterization and epidemiology, transgenic field trials, biosafety, IPR, food safety 
deployment, gene flow. 
3 The data presented for South Africa is from a paper developed by Quemada (2003). Very preliminary data for South Africa was 
presented in the Next Harvest conference by Brink and Koch (2002). Estimate for South Africa￿s virus resistant potatoes are for 
the total regulatory span. 
 
 
7. PHENOTYPES AND TRANSGENES 
Specific transgenes or gene groups were identified and classified according to the 
phenotype expressed. This allows comparisons of regulatory information available and expected 
for genes in wide use, or those that are more unique. The entire set of 209 events could not be 
included here, since detailed information on genes was not always available. Table 3 presents 
five of the eight phenotypes having the highest number of clearly identified genes or gene 




There are primarily three gene groups with sufficiently robust utility and suitability for 
wide use. The first gene group consists of Cry genes from Bacillus thuringiensis (Bt genes) that 
provide insect resistance.  The second group consists of coat proteins of plant viruses used for 
virus resistance, and the third consists of genes conferring herbicide tolerance.  Most other gene 
groups and their associated phenotypic traits have not yet demonstrated robust applicability in 
the field. For example, no gene group has yet to confer effective fungal resistance, although 
much experimental activity has been spent on investigating the glucanases and chitinases.  
Similarly, no group of genes has been shown to reliably confer bacterial resistance in the 
field, even though many investigators have studied the effects of antimicrobial peptides.  Thus, 
there is only limited success in developing crops with traits other than insect resistance, virus 
resistance, and herbicide tolerance. The large number of single gene approaches means that 
researchers are testing numerous alternatives to achieve traits of interest, which may lead to 
identifying utility of other gene groups. 
Five genes were labeled as confidential. Such confidentiality indicates that countries are 
becoming aware of the need to protect intellectual property rights in the earlier stages of 
development. These confidential genes could be publicly developed or received from the private 
sector under confidential agreements. In either case, they demonstrate that some research 
institutes are finding other than fully public means to use and develop novel genes.  
When developing country scientists use genes made available for research, licensed, or 
derived from collaborative research, greater amounts of data are available to enable regulatory 
decisions. The more unique the gene and crop used for transformation, the additional data can be 




assemble such data, particularly if the genes are novel enough to warrant food safety testing for 
commercialization. 
Among the genes or gene groups listed below, the Cry genes, coat protein genes, and 
herbicide tolerance genes can be expected to move through regulation with fewer requirements 
for additional data. This is because numerous safety reviews have been conducted on these genes 
in several countries. However, this does not rule out the need for tests to address specific 
environmental or biodiversity concerns, as results of such tests may not be transferable from one 
country to another. 
The more unique or singular genes shown in Table 3 include 16 insect resistance genes, 
seven genes that are not coat protein approaches, and antimicrobial peptides or sarcotoxin, used 
for blast resistance. In contrast to well-known genes for herbicide resistance, the more unique 
genes will require more information for biosafety review, and have fewer options to benefit from 
data from other sources.  
 
8.  REGIONAL FINDINGS 
By continent, researchers in four African countries (including North and Sub-Saharan 
Africa) completed 54 events, scientists in seven Asian countries produced 111, those in four 
countries in Latin America accomplished 30, and Bulgarian researchers produced eight (table 4). 
At the present time, the greatest number of events has been generated in Asia, though only the 
Philippines has approved a food crop for testing and commercial production. Our work among 
transition economies has just started; hence, we only have data from Bulgaria for East Europe. 




Table 3--Genes and gene groups clustered within 5 phenotypic groups 
Phenotype 
Category 
Gene or gene groups 
 
Number of events 
 
IR     51
 Bt  35 
  GNA (Snowdrop lectin)  5 
 Pin  4 
 Trypsin  inhibitor  2 
  Bt and Trypsin inhibitor  2 
 Gall  midge(Gm2)  1 
 Confidential  1 
  Alpha amylase inhibitor  1 
VR     55
 Coat  protein  48 
 Replicase  3 
 Nucleoprotein  gene  1 
  Coat protein and Reporter genes  1 
  Coat protein and replicase  1 
  Antisense to TYLCV  1 
FR     21
 Glucanase,  Chitinase  6 
 Glucanase,  PGIP2  2 
 Confidential  2 
  Chitinase and AP24   2 
 Chitinase  2 
 Blast  resistance  2 
  PGIP1 and PGIP2 - isolated at VOPI  1 
 Grape  resveratrol  1 
 Glucanase,  PGIP3  1 
  b32, PGIP2 (VOPI), and other selected anti-fungal genes  1 
 AP24,CH5b,GLN3  1 
HT     11
 PAT  4 
 EPSPS  2 
 BAR  2 
 AHAS  2 
 PsbA,atrazin  1 
BR     8
 Xa21  5 
 Sarcotoxin  1 
 Antibacterial  1 
 Antimicrobial  peptides  1 
IR= Insect resistance, VR=virus resistance, FR=fungal resistance, HT=herbicide tolerance, BR=bacterial resistance. 
 
 
These survey results by region capture several interesting points. First, while Asia is the 




region￿s success is directly tied to the degree of investments in research, and, the success that 
China (and to a lesser degree Indonesia and India) have had in insect resistant GM cotton 
approvals. Africa stands in sharp contrast to Asia, as once all events from South Africa are 
excluded, there is little GM crop research elsewhere. Latin America advancement in GM crop 
research lies in between Asia and Africa. Again, however, once Brazil, as the region￿s 
biotechnology research leader, is separated from the other Latin American countries studied, the 
amount of GM crop research declines in the region.  
Table 4--Number of transformation events by region. 
 
Continent  Country  Number of Events  Sub-totals 
Africa Egypt  17 
 Kenya  4 
 South  Africa  28 
 Zimbabwe  5 
54
Asia China  30 
 India  21 
 Indonesia  24 
 Malaysia  5 
 Pakistan  5 
 Philippines  17 
 Thailand  7 
109
East Europe  Bulgaria  8  8
Latin America  Argentina  21 
 Brazil  9 
 Costa  Rica  5 
 Mexico  3 
38
All   209  209
 
While research is underway elsewhere, it is clear that Asia has made a significant 
commitment to GM crop research (ADB 2001). The region hosts the largest number of countries 
engaged in GM crop research as well as the highest percentage of events in testing. Africa, with 
the exception of South Africa, is seriously lacking in capabilities and resources to consider such 
research (Alhassan 2003; UN ECA 2002), and in many cases, countries are just exploring the 




potential markets are evolving (such as insect resistant cotton), albeit subject to uncertainties 
regarding the use and trade of GM crops.  
As shown in Table 5 below, Asia conducts research on the largest variety of crops and 
events, followed by Africa, particularly South Africa.  Bacterial resistance is the most limited, 
while the single most important group is the expression of insect resistance in Asia. As will be 
discussed later, such commonalities could lead to new forms of collaboration among neighboring 
countries, including new opportunities for exchanging transgenes and germplasm.  
 
Table 5--Regional distribution of phenotypic traits by continent.  
Continent Crops AP  BR F R HT IR PQ VR Stacked OO Total
  (number) Number of events 
                  
Africa 20 8  1  7 4 11 5 18    54
Asia 30 11  6  6 2 39 10 27 4 4 109
East Europe  4 4  1   1    2    8
Latin 
America 12 3    8 4 1 2 8 5 7 37
                  
 All           46  26  8  21 11 51 17 55 9 11 209
AP- Agronomic Properties; BR- Bacterial Resistance; FR- Fungal Resistance; HT- Herbicide Tolerance; IR- Insect 
Resistance; OO￿ Other; PQ- Product Quality; VR- Virus Resistance. 
 
 
South Africa presents an important case study. South Africa has devoted an 
appreciable amount of money to biotechnology research and development. Though the South 
African research program was relatively unfocussed in its early years, it has become more 
targeted and better coordinated with the enactment of the Biotechnology Strategic Plan and the 
BRICS (Biotechnology Research Innovation Centers), and under the pressure of reduced 
financial support for research in the Agricultural Research Council.  
Furthermore South Africa￿s requirement that research proposals be linked to industrial 
applications or development partners is ensuring that agbiotech products are developed with 




Public Understanding of Biotechnology
14 that promotes informed decision making among the 
population (Koch, personal communication 2004). South Africa has an established biosafety 
process that reviews all activities with GMOs and has recently ratified the Cartagena Protocol on 
Biosafety. 
9. REACHING THE FARMER 
Participating countries were asked to share preliminary plans as to how GM crops will be 
disseminated to farmers. Results from the study indicate that in general, such plans have not been 
established￿scientists have either not determined suitable mechanisms with which to reach 
farmers, or they intend to rely on the usual public sector methods of dissemination (Figure 7). 
Plans are further complicated by such factors as the uncertainty about the time lines for 
regulatory approvals and the difficulty scientists face in determining when to introduce GM 
crops and crop management techniques to farmers.  
Some research institutes have sought partnerships to complete development of their GM 
research products, as one means to move research through the regulation process and onto public 
or private producers. However, few of these partnerships have developed, including those with 
the private sector. This reflects the paucity of working options available, and the difficulty of 
determining farmer acceptance when it is not possible to supply seed for observation and testing.  
Finally, such partnerships and time lines reflect only the estimated capacity of these institutes to 
offer/supply a product. The partnerships reported do not include time needed for acceptance, to 
engage farmers, and, to meet appropriate seed or plant material suppliers.  
Who is responsible for establishing partnerships in these situations? In many cases, it 
goes well beyond the abilities of scientists, which may also account for the percentage of general 
                                                 




answers supplied. Research institutes need additional expertise to address the specifics above, 
maintain biosafety standards, and seek regulatory approval with responsible partners.  
Economically advanced countries experience a rapid rise in the number of research 
partnerships involving commercial firms, universities, non-profit organizations, and public 
institutions (see for example, European Commission 2002). In plant biotechnology, public-
private collaboration is usually emphasized in order to ensure that the products from agricultural 
research actually reach farmers￿ fields. Considering the time and costs involved in regulatory 
processes, it is essential that roadmaps toward product development and farmer interaction ￿ and 
potential roadblocks ￿ be conceived early in the R&D process. The local and international 
private sector would play a key role in this process, given their increasing experience in 
commercial development and eventual release of GM crops. However, examples of successful 
public-private partnerships in plant biotechnology are still rare (Spielman and Von Grebmer 
2004). 
 Data collected in our survey reflect the general situation. Some form of partnership was 
recorded for 82 events or 39 percent of the total. Single, public R&D institutions conduct the 
largest proportion, 61 percent, of research. Of the 80 partnerships recorded, the majority (48 
events) involved public-public collaboration, most often between public research institutions in 
the same country. In a number of cases, partnerships and technology transfers were undertaken 





Table 6--Types of institutional arrangements or collaboration used for this research 
Institutional arrangement  Asia Latin America Africa Bulgaria  All
   
Single public institution  71 22 28 8  129
Public/Public 25 9 13 0  47
Public/Private 1 7 7 0  15
Public/Foundation/Public 8 0 0 0  8
Public/Private/other 1 0 5 0  6
All other (no private 
collaboration) 3 0 1 0  4
   
Total 109 38 54 8  209
 
Private foundations, such as the ISAAA, are reported to be involved in 11 events, playing 
a brokering role in international technology transfer from the public or private sector. CGIAR 
centers were reported in three cases, confirming the CGIAR￿s limited role in GM crop 
development and the wide diversity of crops and genes being used (Figure 3, Table 3).
15  
Public-private collaboration was found in 21 cases (eight percent of all events) including 
a number of examples from African countries (Egypt, Kenya, and South Africa). The 
international private sector is involved in the majority of these cases, while local seed companies 
still play a minor role. Respondents were often not able to provide details of these public-private 
partnership arrangements, due to their confidential nature, but our limited information points to 
the use of contracts (research agreements, material transfer agreements) to govern public-private 
collaboration. 
However, little is know of these partnerships in terms of relative strengths of each 
partner, and what conditions are critical for such partnerships to be of value to society (Spielman 
and Von Grebmer 2004). The key point is to assure equal footing between public and private 
                                                 
15 Presentation of similar information from the CGIAR centers themselves may provide other and more 
extensive partnerships. However, there is only limited partnership information available at this time (Spielman 





contributions. This is important in terms of genetic resources, as mentioned above, to ensure 
benefit, as well as for transgenes. The topic warrants further research to expand the knowledge 
and understanding of partnership arrangements and expectations.  
A separate finding was that of all the types of partnership, no evidence was found of 
South-to-South collaboration. There are many reasons for this, including a lack of formal 
networking mechanisms, extremely limited resources, and a need for information on genes 
employed. As information becomes publicly available and new technology exchange 
mechanisms are created, such as the African Agricultural Technology Foundation (AATF)
16, 
more opportunities for South-South transfer may arise.  
Brazil presents a unique approach. The case of Brazil contrasts to that of all other 
countries participating in the study. The number of transgenic events for Brazil indicates 
significant commercial involvement. Embrapa has been establishing partnerships with the private 
sector to explore commercial crop improvement, and this is the source of data used. These 
relationships are established through research contracts and later commercial contracts that set 
forth the terms and conditions for technology transfers to the private sector, the distribution of 
royalties and other arrangements.   
Of the 46 transgenic events reported from Brazil, 37 were undertaken by commercial 
companies (local and international)
17, while nine events were produced by public research. These 
37 events were primarily for insect resistance (IR) and herbicide tolerance (HT). These are well 
known traits for commercial research and investment. More than half of these events are in 
maize, followed by cotton, soybeans, and sugarcane.  
                                                 
16 http://www.aftechfound.org/ 
17 These 37 events are not included in the total 209 events in this study as they are purely commercially and our 




Public research spans five crops, with soybeans most important, followed by maize, 
potatoes, papayas and beans. Of the nine public events (included in the total 209), the phenotypic 
traits include primarily herbicide tolerance and virus resistance.  
Embrapa can take advantage of commercial research opportunities, as there is a 
significant seed market potential in Brazil. This gives Embrapa more outlets for its technologies, 
and allows the Institute to indirectly take advantage of the additional sources of improved 
germplasm. In other developing countries, such stable, market-oriented, and seed distribution 
networks barely exist, or do not exist at all, creating almost sole dependence on the public sector 
for agricultural innovation. This is especially true for countries not allowing import, testing and 
possible approval of commercial transgenic crops. With sole dependence on public sector, and 
no ability to import GM crops for testing, farmers stand to lose in many different ways.  
However, Brazil is also affected by judicial moratoria that resulted from complications 
associated with its biosafety and environmental legislation. While such private research offers 
local potential and benefit, it will not reach farmers while the current legal and political 
environment prevent GM crop testing and use. The impact is already evident in the number of 
events at the advanced testing stage, (36 of a total of 42 events), that are not moving to scale-up 
trials and or commercial approval stages.   
The latest news from Brazil is that Congress should decide during the first half of 2004, 
on a new biosafety law that is supposed to give more freedom to researchers by removing 
excessive procedures while still imposing the safe evaluation of field tests. Glyphosate resistant 
soybean has been planted illegally since 1998, but in 2002 and 2003 the harvested crop was 
made legal by two specific laws. This has moved Brazil to the list of countries that now export 




may follow the same path. These facts, and general changes around the world with respect to 
agricultural biotechnology and biosafety, are signaling the Brazilian Government and Congress 
that such a timely review of its GMO policy is needed (Contini et al. forthcoming). 
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10. PUBLIC RESEARCH AND POLICIES FOR GM CROPS  
ENVIRONMENTAL SAFETY: CROPS AND PHENOTYPES 
Addressing concerns regarding environmental safety of GM crop introductions is 
essential. The summary data presented in this paper can provide a focus for expected 
environmental risk assessments. Common elements of current and future assessments, as 
determined for confined or commercial use, can be identified from such information, whether by 
crop, country, gene or phenotype. Ideally, this information would be shared among countries in 
conjunction with the development and implementation of the Biosafety Clearing House (BCH)
18, 
so that queries on risk assessments can be carried out based on accumulated experience.  
As expectations for relevant risk assessments are developed, it would be possible to 
organize work with countries sharing common gene and crop experiences. This presents 
                                                 




opportunities for South-South collaboration and data sharing, with the intent to minimize 
redundancies while maximizing exchange of expertise. The range of crops covered by our survey 
is very large, and so various assessments can be expected, depending on their specific 
characteristics such as: the plant￿s biological properties, their dispersal and ecological behavior, 
proximity to center of origin or diversity, and effects of the transgene on target and non-target 
species.  
Experiences can also be shared with regard to experimental design, special environmental 
concerns (as per gene and crop), review of trials to date, and reasons for or against its 
advancement to commercial trials. This type of information, on the actual testing conducted, is 
not well known and often not documented in regulatory dossiers.  
Our main concern is not to minimize the need for such tests, but to strive for consistency 
with their respective degree of containment and that testing is based on solid and comprehensive 
sources of information. Such background information and directions to applicants could clearly 
justify why a test is called for, how it should be designed, and the type of information needed. 
This increases regulatory proficiency and minimizes applicant￿s costs.  
TRANSGENES: PROGRESS AND NEEDS.   
As seen in Table 3, numerous transgenes are under development and testing for important 
phenotypic traits. Some of these genes are well understood and documented, while others are 
more unique and experimental. In either case, there is little consolidated information among 
developing countries as to gene/phenotype stability in the field. The conference participants 
recognized the need for consolidated information regarding genes, phenotypes, stability and 




Participants have greater familiarity with genes identified for insect and virus resistance, 
and herbicide tolerance (61 percent of total events). Others are more unique or of local 
derivation, or still very experimental. The widest variety of such genes was seen in the 
phenotypic categories of agronomic properties, fungal resistance, and protein quality 
enhancement. Included in these categories are genes for drought resistance, improved nutritional 
quality, salt tolerance, various combinations of glucanase and chitinase genes for fungal 
resistance, and applications of Xa21 for blight resistance, to name but a few. In addition, these 
genes are found in multiple crops, across many countries.  
Collective knowledge on this array of transgenes can also be used to negotiate access and 
field-of-use agreements and to ensure intellectual property concerns and constraints are 
identified and resolved. While not covered in depth, these issues are preventing some of the gene 
technologies from moving forward in development (Figure 7). New forms of IP agreements can 
be approached through ￿humanitarian￿ use-type agreements, or IP donation facilities (Atkinson 
et al. 2003; AATF). Other factors, such as potential utility, the IP position of the technology 
owner, existence of competing gene constructs, and industrial marketing strategies can have a 
bearing upon licensing negotiations and conditions. Many of these GM crops have significance 
for within-country or regional trade, but not international. Reviewing IP concerns should take 
this into account, as these crops are not entering international trade, or shipment to countries 
where biotechnology patents are filed (Binenbaum et al. 2003). 
Survey data was not collected for construct details, promoters, or markers. Meeting or 
exchanging data here is also possible, as many of the molecular characteristics are common as 




environmental consequences. When data is not available from any provider, then further 
environmental assessment trials are especially justified.  
Finally, partnerships can help develop and provide information on the other 82 genes, or 
gene combinations, to increase understanding of modality and to ensure greater exchange of 
information for regulatory purposes. The sooner such opportunities are presented, the sooner 
gene stability, safety, and efficacy can be determined. However, as indicated in our findings on 
partnerships and multi-institute collaboration, such opportunities are limited.  
RESEARCH AND POLITICAL UNCERTAINTY  
This study shows how public institutes in the developing world advance GM crop 
research. Successful research has been recorded for 46 crops, with many waiting for further 
confirmation in field and scale-up trials. More advanced, or larger scale trials will let institutes 
know if their research is competitive when compared with available commercial opportunities.  
Farmer, or other field or quarantine testing, enables researchers and regulators to determine 
whether GM crops fill an important agricultural niche, or provide desirable traits in crops not of 
interest to the private sector. 
However, this research is conducted during a time of political and legislative uncertainty 
that influences the regulatory system, and the potential use, risk, and advantages of genetically 
modified plants (Cohen and Paarlberg 2002). As discussed by Paarlberg (2000, 2001), a matrix 
of policies or actions determine a biotechnology acceptance gradient from precautionary to 
promotional. Of those determinants, this study focuses most specifically on biosafety regulation, 
actual GM crop approvals, and opportunities from confined field trials. Table 7 summarizes 
these comparisons. It reflects the fact that while progress is seen for approvals of GM cotton, 




Each participating country has confined trials underway, completed, or in multiple years 
of trials. However, eight of these countries have granted no approval for GM crops, while for 
eight other countries, primary approvals were made for GM cotton (Table 7). This table shows 
the year in which biosafety regulations and systems began, with each country having more than 
12 years of experience, but with different end points, as in laws, regulations, or guidelines. The 
number of actual approvals and the year they were most recently granted serves as a measure of 
political or national acceptance or concern. If approvals are few and long between, it will be 
difficult to achieve timely advancement of publicly derived GM crops, thus limiting 
opportunities to interact with farmers.  
Uncertainty comes not only from policy at the political level, but also from regulatory 
requirements at the research level. Additionally, but less visible it comes from the combination 
of genetic resources used for transformation and the particular gene inserted. When appropriate 
trials are delayed, or extra years added, whether due to breeding, testing, certification or 
regulation, new crops run the risk of being irrelevant by the time of approval.   
For example, biotic stresses evolve and mutate, so that genes conferring useful resistance 
at one point in time may not in another, or resistance genes do not perform in the field, even 
though they provided resistance in experimental stages. Once virus resistant GM sweet potatoes 
received import and quarantine approval for Kenya, the Kenyan Agricultural Research Institute 
in confined field trials could rapidly test them where genetic protection proved insufficient. The 
longer such testing is postponed due to political or regulatory uncertainty, the longer events must 
be maintained in laboratories or screenhouses, delaying understanding and evaluation of their 




Table 7--Current regulatory status, approvals and testing of participating countries 




National legal structure: 






















  No of 
events 
Crops   Year  Number  Number  Mill 
has. 




Regulation 1991  367  5  13.9 
Brazil 1  soybeans  Regulation  1989 339  6  3.0 
Bulgaria  0     Draft Law presently 
national guidelines  
1996 3   <0.5 
China 1    Cotton
3  Ministry of Agriculture 
Regulation, followed by 
State approval  
1993 501
3 3  2.8 
Costa Rica  0    Regulation  1992  17  1   
Egypt  0     Draft law in 
preparation; currently: 
Law from Environment 
Ministry; Regulations 
(decrees): one for GM 
seeds and second for 
GM crops  
1994   7   
India 1  Cotton  Regulations  1989   5  0.1 
Indonesia 0  Cotton  Regulation  1993    0  <0.5 
Kenya 0    Guidelines  and 
regulations  
1991 2  1   
Malaysia  0    Guidelines (law under 
development) 
   2   
Mexico 5  cotton, 
tomato, 
soybeans 
Draft Law; Regulations 
and Standards  
1995 241  2  <0.5 
Pakistan 0   Guidelines  under 
development 
   2   
Philippines 1 Maize  Regulation  1990    1   
South Africa  5  cotton, 
maize, 
soybeans 
Law 1990  172  7  0.4 
Thailand 0    Guidelines  1990    2   
Zimbabwe   0    Law  1990       
Total   21          44  <21.7 
1 Usually in the form of a Ministerial decree or similar instrument under existing phyto-sanitary or environmental law. 
2 Argentina has seven events listed here as we count the three HT/IR maize approvals as one type of event. 
3 This number was reported for China, from 1997 ￿ 2002; while over 59 applications have been granted commercial approval, it 
is the GM cotton reported here that is approved for use by farmers. No transgenic food or oil crops have been approved to date 
(Jia and Peng 2002) 
Sources: Agbios 2003; James 2003; NH data; UNIDO 2003; For field trials: CONABIA 1999 (Argentina), SAGARPA 2004 
(Mexico), CTNBio 2001 (Brazil), OECD Biotrack 1999 (Bulgaria), Huang et al 2002 (China), and National Department of 





Will policies and research in the developing world stimulate the safe use of publicly 
developed GM food crops? We addressed this question with an analysis that takes readers from 
continent and country to genes and genetic resources used for transformation. To do so, the paper 
summarized information for GM crop research conducted by public research institutes in 16 
developing and transition economies. This information will help scientists, policy makers, and 
regulators understand their respective countries￿ public GM research and help address the 
question above. Further analysis￿more in-depth and specialized examination of the key 
issues￿ will be conducted in direct consultation with the participating countries.  
Research institutes covered in this study demonstrate capabilities across 46 plants, several 
different phenotypes, and the ability to use transgenes together with available genetic resources. 
In so doing, scientists have harnessed an assortment of genes in pursuit of traits relevant to 
farmers. Some have also gained familiarity with regulatory dossiers as needed for biosafety 
determinations. The range and diversity of these crops is wide, exceeding that carried out 
through international programs. However, desired phenotypes are few when compared to traits 
being developed by multinational firms or advanced research institutes in industrialized countries 
(Nuffield Council on Bioethics 2004). 
The public sector is a viable, but largely unproven, player in the bioengineering of local 
crops.  While the participating institutes and scientists have developed many crop/phenotype 
combinations, which if found efficacious, and deemed safe, have not yet reached farmer￿s fields 
for trial and observation. This viability of research comes from capability and expertise in 
modern biotechnology created over the last decades and, equally important, the need for 




also provides human resources for many of the regulatory decision-making bodies, insight into 
national councils, and ensures program continuity.  
On the policy front, we see that regulatory systems and policies have been under 
development for over 12 years. Some of these systems have already conducted biosafety 
assessments, and have determined which crops are acceptable for trials and use. However, even 
with this progress, regulatory decision-making remains complicated, affected by conforming to 
the Cartagena Protocol for Biosafety, and, are subject to delays or moratoria. The fact that there 
are approximately 20 percent of the 209 events in various phases of confined testing indicates 
opportunities for advancement of public sector research products. However, the longer the 
waiting period, the more likely the trait and or germplasm becomes ineffective as disease 
pressures change and more productive varieties are released.   
A combined policy / institutional issue also arises for public GM crops because so many 
institutes work alone, without research or development partners. The data and analysis presented 
here can reduce such isolation by finding commonalities among crops, genes, regulatory stages, 
and collaboration. With this information, private firms and public research institutes can pursue 
greater collaboration based on these commonalities and complementarities.  
Moreover, this information can be used to organize greater South-to-South collaboration, 
a mode of partnership that does not presently exist in any appreciable quantity. Greater South-
South collaboration will provide one more way to strengthen inter-institutional research and 
experiences. This can occur by building on common approaches, genes, and stage of regulatory 




The information reviewed in this study can also inform readers of parallel research in 
their own country, in other regions, and internationally. This can be valuable when selecting 
transgenes, considering regulatory requirements, and genetic resources available, or needed.   
Building on these new opportunities to strengthen public GM crop research and exchange 
experiences, does not mean that all decisions are in the researcher￿s hands alone. Rather, it is a 
process involving several policy dimensions concerning the regulatory system, the political and 
trade environment, the management of development opportunities and partnerships, and keeping 
in constant dialogue with farmers to address their needs and the needs of specific communities.  
However, all of these events and policies can also be used against the very technologies 
they are there to evaluate and to advance once proven. Delays can mean rising costs, lack of 
impact at the rural level, regulatory requirements in need of clarification, and more direct 
accountability. Such concerns are emerging issues in developing countries. The combined effect 
is delayed impact and uncertainty of the technologies, both of which are used by biotechnology￿s 
detractors nationally and internationally.  
We have recognized policy, political and institute changes where efficiencies could be 
gained, while assuring safety and efficacy of GM crops. A combination of these changes and 
farmer testing of products from public research means a rapid assessment of success or failure. 
Clearly immense progress has been made on all fronts; but efforts are still needed to ensure that 
polices and institutes in the developing world stimulate the safe and relevant use of these new 
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Table A-1--Biotech approvals for Planting in the developing world 
Country Trait  Cotton  Maize  Soybean  Tomato  Grand  Total 
Argentina  Count  of events  2  4  1  7 
 Glufosinate    1      1 
  Herbicide  tolerance  1  1  1  3 
 
Herbicide tolerance + 
insect resistance   3      3 
 Insect  resistance  1  1      2 
Brazil  Herbicide  tolerance    1  1 
China Insect  resistance  1        1 
India Insect  resistance  1        1 
Mexico Delayed  ripening        1  1 
  Herbicide  tolerance    1  1 
 Insect  resistance  1        1 
Philippines Insect  resistance    1      1 
South  Africa  Herbicide  tolerance    1  1 
 Insect  resistance  1  1      2 
Uruguay Herbicide  tolerance    1  1 
Grand Total    6  8  5  1  20 
          
Events count    6  6  5  1  18 
 
Note: Events are counted as the unique combination of trait/country/crop. For example, the 3 biotech approvals for 
Argentina in maize HT/IR in Agbios database listed here are counted as 1 event.          
 
Source: Authors calculations using Agbios data from ￿Global Status of Approved Genetically Modified Plants￿ in 
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